Source disclosure: February 06, 2026
Oncolys BioPharma Inc. [4588.T]
TOKYO, Feb 06 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) reported non-operating items for its fiscal year ended December 31, 2025.
The company recorded total extraordinary income of ¥4 million from January 1, 2025, to December 31, 2025, primarily due to interest income of ¥3 million. Additionally, it recognized ¥25 million in foreign exchange gains from asset revaluation during the period from October 1, 2025, to December 31, 2025. In terms of non-operating expenses, Oncolys BioPharma incurred ¥31 million from January 1, 2025, to February 29, 2025, mainly attributed to stock issuance costs and share-based compensation expense.
Furthermore, the company reported additional non-operating expenses of ¥9 million from July 1, 2025, to September 30, 2025, largely due to further stock issuance costs and interest payments. Regarding special losses, Oncolys BioPharma recorded a total of ¥2 million from January 1, 2025, to June 30, 2025, stemming from impairment losses related to headquarters renovation projects. A similar amount of ¥2 million was also noted from November 1, 2025, to December 31, 2025, for the same reasons.
For more detailed impacts on performance, investors should refer to the earnings release published.
AI-translated content. 🟢 Confidence: High See terms • Original filing